These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 17017973)

  • 1. New treatment options using 5-HT3 receptor antagonists in rheumatic diseases.
    Müller W; Fiebich BL; Stratz T
    Curr Top Med Chem; 2006; 6(18):2035-42. PubMed ID: 17017973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [5-HT3 receptor antagonist als analgetics in rheumatic diseases].
    Müller W; Fiebich BL; Stratz T
    Z Rheumatol; 2006 Oct; 65(6):546, 548-52. PubMed ID: 16450149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of 5-HT3 receptor antagonists in various rheumatic diseases--a clue to the mechanism of action of these agents in fibromyalgia?
    Stratz T; Müller W
    Scand J Rheumatol Suppl; 2000; 113():66-71. PubMed ID: 11028836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Local treatment of rheumatic diseases with the 5-HT3 receptor antagonist tropisetron].
    Stratz T; Müller W
    Schmerz; 2003 Jun; 17(3):200-3. PubMed ID: 12789487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Local treatment of tendinopathies and myofascial pain syndromes with the 5-HT3 receptor antagonist tropisetron.
    Müller W; Stratz T
    Scand J Rheumatol Suppl; 2004; 119():44-8. PubMed ID: 15515413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intra-articular treatment of arthritides and activated osteoarthritis with the 5-HT3 receptor antagonist tropisetron. A double-blind study compared with methylprednisolone.
    Samborski W; Stratz T; Mackiewicz S; Müller W
    Scand J Rheumatol Suppl; 2004; 119():51-4. PubMed ID: 15515415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-HT3 receptor antagonists: a new therapeutic approach in rheumatology? Proceedings of a symposium. Frankfurt, Germany, February 12-13, 2004.
    Scand J Rheumatol Suppl; 2004; 119():1-80. PubMed ID: 15584135
    [No Abstract]   [Full Text] [Related]  

  • 8. [5-HT3-receptor-antagonists in therapy of rheumatic diseases].
    Müller W; Stratz T
    Z Rheumatol; 2003 Feb; 62(1):39-41. PubMed ID: 12624802
    [No Abstract]   [Full Text] [Related]  

  • 9. [Pain modification by the 5-HT3 receptor antagonist tropisetron in secondary fibromyalgias].
    Stratz T; Müller W
    Fortschr Med Orig; 2002; 120(1):17-20. PubMed ID: 14518353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concluding remarks and outlook for the use of 5-HT3 receptor antagonists in rheumatology.
    Pongratz D; Stratz T; Müller W
    Scand J Rheumatol Suppl; 2004; 119():79-80. PubMed ID: 15515422
    [No Abstract]   [Full Text] [Related]  

  • 11. Spinal 5-HT3 receptor mediates nociceptive effect on central neuropathic pain; possible therapeutic role for tropisetron.
    Nasirinezhad F; Hosseini M; Karami Z; Yousefifard M; Janzadeh A
    J Spinal Cord Med; 2016; 39(2):212-9. PubMed ID: 26338446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential pharmacotherapy for subgroups of fibromyalgia patients with specific consideration of 5-HT3 receptor antagonists.
    Seidel MF; Müller W
    Expert Opin Pharmacother; 2011 Jun; 12(9):1381-91. PubMed ID: 21323622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Local-anesthetic like inhibition of the cardiac sodium channel Nav1.5 α-subunit by 5-HT3 receptor antagonists.
    Van't Klooster MP; Foadi N; Hage A; Stoetzer C; Wegner F; Eberhardt M; Leffler A
    Eur J Pharmacol; 2016 Oct; 789():119-126. PubMed ID: 27401036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tropisetron suppresses colitis-associated cancer in a mouse model in the remission stage.
    Amini-Khoei H; Momeny M; Abdollahi A; Dehpour AR; Amiri S; Haj-Mirzaian A; Tavangar SM; Ghaffari SH; Rahimian R; Mehr SE
    Int Immunopharmacol; 2016 Jul; 36():9-16. PubMed ID: 27104313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From Chemotherapy-Induced Emesis to Neuroprotection: Therapeutic Opportunities for 5-HT3 Receptor Antagonists.
    Fakhfouri G; Mousavizadeh K; Mehr SE; Dehpour AR; Zirak MR; Ghia JE; Rahimian R
    Mol Neurobiol; 2015 Dec; 52(3):1670-1679. PubMed ID: 25377794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of serotonin- and 2-methylserotonin-induced pain may reflect 5-HT3 receptor sensitization.
    Giordano J; Gerstmann H
    Eur J Pharmacol; 2004 Jan; 483(2-3):267-9. PubMed ID: 14729116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tropisetron attenuates cisplatin-induced nephrotoxicity in mice.
    Zirak MR; Rahimian R; Ghazi-Khansari M; Abbasi A; Razmi A; Mehr SE; Mousavizadeh K; Dehpour AR
    Eur J Pharmacol; 2014 Sep; 738():222-9. PubMed ID: 24905858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-HT3 Receptor Antagonists for Propofol Injection Pain: A Meta-Analysis of Randomized Controlled Trials.
    Wang W; Zhou L; Wu LX; Wang T; Zhang CB; Sun L
    Clin Drug Investig; 2016 Apr; 36(4):243-53. PubMed ID: 26860485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tropisetron attenuates amyloid-beta-induced inflammatory and apoptotic responses in rats.
    Rahimian R; Fakhfouri G; Ejtemaei Mehr S; Ghia JE; Genazzani AA; Payandemehr B; Dehpour AR; Mousavizadeh K; Lim D
    Eur J Clin Invest; 2013 Oct; 43(10):1039-51. PubMed ID: 23937291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analgesic effects of 5-HT3 receptor antagonists.
    Riering K; Rewerts C; Zieglgänsberger W
    Scand J Rheumatol Suppl; 2004; 119():19-23. PubMed ID: 15515407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.